TCRX
TCRX
NASDAQ · Biotechnology

Tscan Therapeutics Inc

$1.03
+0.12 (+13.14%)
As of Feb 8, 2:17 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 16.47M 16.16M 15.23M
Net Income -1,820,896 -2,032,977 -1,710,895
EPS
Profit Margin -11.1% -12.6% -11.2%
Rev Growth +21.6% -2.0% -5.3%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 16.08M 15.92M 17.53M
Total Equity 24.60M 24.83M 23.68M
D/E Ratio 0.65 0.64 0.74
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -2,687,351 -2,828,117 -2,426,513
Free Cash Flow -1,805,522 -1,769,464 -1,134,231